UNITY by BILLIONTOONE

Early detection changes lives.

UNITY Fetal Risk™ Screen is the only clinically validated NIPT that provides direct fetal risk assessment for up to 14 recessive and X-linked conditions including cystic fibrosis, spinal muscular atrophy (SMA), hemoglobinopathies, and more. Early detection empowers providers and patients to initiate timely interventions, connect with specialized care, and explore emerging treatments.

Conditions Screened	Carrier Frequency	Available Interventions
Cystic Fibrosis Creates thick mucus buildup affecting the lungs and digestive system. New CFTR modulators may improve symptoms and life expectancy.	1 in 38 General Population 1 in 29 Ashkenazi Jewish	
Spinal Muscular Atrophy Causes progressive weakness in muscles that control breathing, eating, and movement. Several FDA-approved treatments are available and may dramatically improve function when started early.	1 in 54 General Population	
Sickle Cell Disease* Causes misshapen red blood cells which lead to anemia, pain crises, and infections that may result in severe complications. Recent FDA-approved gene therapies can alleviate symptoms and improve quality of life.	1 in 33 General Population 1 in 8 African American	
Alpha-Thalassemia Causes anemia which varies in severity. Mild forms cause few problems and more severe forms may cause pregnancy complications.	1 in 112 General Population	
Beta-Thalassemia* Produces abnormal hemoglobin, leading to anemia and related health issues. New treatments like gene therapy are available and may lead to less symptoms.	1 in 33 General Population	

Emerging Treatments and Therapies

Gene or Enzyme Therapies

Early detection enables access to therapies that may significantly improve outcomes

Dietary Modifications

May improve outcomes and help alleviate symptoms

Multidisciplinary Care

Early detection connects families with specialists for immediate postnatal care

Early Intervention Programs

Intervention programs and IEPs support development with demonstrated benefits

* BillionToOne covers cord blood collection costs and banking fees for the first year for patients who receive a UNITY Fetal Risk Screen high risk *HBB* result.

Conditions Screened	Carrier Frequency	Available Interventions
Canavan Disease Causes progressive neurological damage leading to developmental delays, weak muscle tone, and vision loss. Symptom management, medication, nutrition and developmental support, may improve daily life. Gene therapies are also under investigation.	1 in 439 General Population 1 in 44 Ashkenazi Jewish	
DMD-Associated Dystrophinopathies Leads to progressive muscle weakness and loss of function, often affecting the heart and lungs over time. FDA-approved gene therapies and exon-skipping treatments may slow disease progression and improve mobility.	1 in 717 General Population	
Familial Dysautonomia Disrupts the autonomic and sensory nervous systems, causing gastrointestinal dysfunction, blood pressure fluctuations, and insensitivity to pain. Symptom management, like medication and nutrition support, may improve daily life.	1 in 402 General Population 1 in 35 Ashkenazi Jewish	
Medium-Chain Acyl-CoA Dehydrogenase Deficiency Impairs the body's ability to break down medium-chain fats for energy, leading to hypoglycemia and other complications. Early diagnosis and dietary management may prevent severe symptoms.	1 in 67 General Population	
PMM2-Congenital Disorder of Glycosylation Affects multiple body systems leading to developmental delays, poor muscle tone, and organ dysfunction. Treatment focuses on managing symptoms, and emerging therapies are being studied.	1 in 70 General Population	
Phenylalanine Hydroxylase Deficiency (PKU) Prevents the breakdown of phenylalanine, an amino acid that can build up and cause intellectual disability and other health concerns if untreated. Dietary therapy and enzyme replacement may help manage symptoms and improve outcomes.	1 in 79 General Population	
Smith-Lemli-Opitz Syndrome Affects cholesterol production, leading to intellectual disability, growth delays, birth defects, and distinctive physical features. Treatments, including dietary cholesterol supplementation, may help manage symptoms.	1 in 71 General Population	
Tay-Sachs Disease Causes progressive neurological decline, vision and hearing loss, and motor dysfunction due to toxic lipid buildup in the brain. Gene and enzyme replacement therapy are being investigated.	1 in 193 General Population 1 in 28 Ashkenazi Jewish	
Fragile X Syndrome Results in moderate to severe intellectual disability with males typically having more severe symptoms than females. There is also a higher chance for other medical and behavioral issues. Treatment focuses on symptom management and support.	1 in 201 General Population	

Contact Us
650.460.2551
support@unityscreen.com

UNITY Complete is a screening test, not a diagnostic test. Any high-risk result should be followed up with diagnostic testing such as CVS or amniocentesis.